Replimune Reports Fiscal Fourth Quarter and Year End 2026 Financial Results and Provides Corporate Update
WOBURN, Mass., June 29, 2026 (GLOBE NEWSWIRE) -- Replimune Group, Inc. (Nasdaq: REPL), a clinical stage biotechnology company…
11,122$
-0,07%
Echtzeit-Aktienkurs Replimune Group
Bid:
Ask:
Nachrichten zur Replimune Group Aktie
Replimune Presents Final First-in-Human Data for RP2 in Advanced Solid Tumors During Oral Presentation at the 2026 American Society of Clinical Oncology Annual Meeting
WOBURN, Mass., May 31, 2026 (GLOBE NEWSWIRE) -- Replimune Group, Inc. (NASDAQ: REPL), a clinical-stage biotechnology company pioneering…
Replimune Presents 3-Year Landmark Overall Survival Analysis from IGNYTE Clinical Trial During Oral Presentation at the 2026 American Society of Clinical Oncology Annual Meeting
WOBURN, Mass., May 30, 2026 (GLOBE NEWSWIRE) -- Replimune Group, Inc. (NASDAQ: REPL), a clinical-stage biotechnology company pioneering…
Replimune melanoma therapy rejected by FDA, shares plunge
Replimune Group (NASDAQ:REPL) shares fell roughly 63% following the company’s disclosure that it received a Complete Response Letter (CRL) from the…
Replimune Receives Complete Response Letter from the FDA for RP1 Biologics License Application for the Treatment of Advanced Melanoma
WOBURN, Mass., April 10, 2026 (GLOBE NEWSWIRE) -- Replimune Group, Inc. (NASDAQ: REPL), a clinical stage biotechnology company pioneering the…
ONCY: Initiating Coverage of Oncolytics Biotech; A Focused Path to Unlocking the Potential of Pelareorep
By David Bautz, PhDNASDAQ: ONCYREAD THE FULL ONCY RESEARCH REPORTWe are initiating coverage of Oncolytics Biotech (NASDAQ: ONCY) with a…
Does Replimune Group (REPL) Have the Potential to Rally 79.61% as Wall Street Analysts Expect?
The mean of analysts price targets for Replimune Group (REPL) points to a 79.6% upside in the stock. While this…
Wall Street Analysts Predict a 65.72% Upside in Replimune Group (REPL): Heres What You Should Know
The consensus price target hints at a 65.7% upside potential for Replimune Group (REPL). While empirical research shows that this…
Replimune Highlights Acral Melanoma Data for RP1 plus Nivolumab at the ESMO Congress 2025
WOBURN, Mass., Oct. 19, 2025 (GLOBE NEWSWIRE) -- Replimune Group, Inc. (NASDAQ: REPL), a clinical stage biotechnology company…
Replimune Reports Fiscal First Quarter 2026 Financial Results and Provides Corporate Update
WOBURN, Mass., Aug. 07, 2025 (GLOBE NEWSWIRE) -- Replimune Group, Inc. (Nasdaq: REPL), a clinical stage biotechnology company…
Bragar Eagel & Squire, P.C. Reminds Investors of Class Actions Against Neogen, Alto, RxSight, and Replimune and Encourages Investors to Contact the Firm
NEW YORK, Aug. 05, 2025 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights…
Shareholders that lost money on Replimune Group, Inc.(REPL) Urged to Join Class Action – Contact The Gross Law Firm to Learn More
NEW YORK, Aug. 04, 2025 (GLOBE NEWSWIRE) -- The Gross Law Firm issues the following notice to shareholders…
ROSEN, NATIONAL TRIAL ATTORNEYS, Encourages Replimune Group, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action First Filed by the Firm – REPL
NEW YORK, Aug. 01, 2025 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm,…
INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Replimune Group, Inc. of Class Action Lawsuit and Upcoming Deadlines – REPL
NEW YORK, July 28, 2025 (GLOBE NEWSWIRE) -- Pomerantz LLP announces that a class action lawsuit has been…
Replimune Group, Inc. Investors: Company Investigated by the Portnoy Law Firm
Investors can contact the law firm at no cost to learn more about recovering their losses…
Replimune Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
WOBURN, Mass., Jan. 10, 2025 (GLOBE NEWSWIRE) -- Replimune Group, Inc. (NASDAQ: REPL), a clinical stage biotechnology company…
Replimune Announces Pricing of Upsized Public Offering
BOSTON, Nov. 25, 2024 (GLOBE NEWSWIRE) -- Replimune Group, Inc. (Nasdaq: REPL), a clinical stage biotechnology company pioneering the…
Replimune Reports Fiscal First Quarter 2025 Financial Results and Provides Corporate Update
WOBURN, Mass., Aug. 08, 2024 (GLOBE NEWSWIRE) -- Replimune Group, Inc. (Nasdaq: REPL), a clinical stage biotechnology company…
Replimune Reports Fiscal Fourth Quarter and Year Ended 2024 Financial Results and Provides Corporate Update
WOBURN, Mass., May 16, 2024 (GLOBE NEWSWIRE) -- Replimune Group, Inc. (Nasdaq: REPL), a clinical stage biotechnology company…
Replimune Group announces CEO transition
…